Ernexa Therapeutics 2025 10-K: $0.0M Revenue, Net Loss $(14.08)M

NodeGuardian · 2026-03-27T16:43:53+00:00

Ernexa Therapeutics reported no revenue in 2025, a decline from $0.582 million in 2024, but improved its net loss to $(14.08) million from $(44.539) million. The company focused on preclinical development, secured financing, and reduced expenses through governance changes.

NodeGuardian

2026-03-27 16:43:53

Abstract generation in progress

Ernexa Therapeutics reported zero revenue in 2025, a significant drop from $0.582 million in 2024, resulting in a net loss of $(14.08) million, an improvement from the prior year’s $(44.539) million loss. The company focused on preclinical development, secured financing through private placements and public offerings, and reduced operating expenses to extend its financial runway. These efforts include optimizing facilities and implementing corporate governance changes like a reverse stock split.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes